Nicholas Stong
Overview
Explore the profile of Nicholas Stong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bock A, Wenzl K, Novak J, Stokes M, Hopper M, Krull J, et al.
Hematol Oncol
. 2024 Nov;
43(1):e70006.
PMID: 39612356
Diffuse large B-cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have a poor prognosis. Genomic profiling has led to a broader understanding of...
2.
Stokes M, Wenzl K, Huang C, Ortiz M, Hsu C, Maurer M, et al.
Nat Commun
. 2024 Aug;
15(1):6790.
PMID: 39117654
Immunochemotherapy has been the mainstay of treatment for newly diagnosed diffuse large B-cell lymphoma (ndDLBCL) yet is inadequate for many patients. In this work, we perform unsupervised clustering on transcriptomic...
3.
Wenzl K, Stokes M, Novak J, Bock A, Khan S, Hopper M, et al.
Blood Cancer J
. 2024 Jun;
14(1):100.
PMID: 38902256
Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To...
4.
Amatangelo M, Flynt E, Stong N, Ray P, Van Oekelen O, Wang M, et al.
Cell Rep Med
. 2024 May;
5(6):101571.
PMID: 38776914
Iberdomide is a next-generation cereblon (CRBN)-modulating agent in the clinical development in multiple myeloma (MM). The analysis of biomarker samples from relapsed/refractory patients enrolled in CC-220-MM-001 (ClinicalTrials.gov: NCT02773030), a phase...
5.
Neri P, Barwick B, Jung D, Patton J, Maity R, Tagoug I, et al.
Blood Cancer Discov
. 2023 Nov;
5(1):56-73.
PMID: 37934799
Significance: We show that IKZF1-bound enhancers are critical for IMiD efficacy and that the factor ETV4 can bind the same enhancers and substitute for IKZF1 and mediate IMiD resistance by...
6.
Sullivan J, Spillmann R, Schoch K, Walley N, Alkelai A, Stong N, et al.
Clin Genet
. 2023 Oct;
105(1):62-71.
PMID: 37853563
Genomic medicine has been transformed by next-generation sequencing (NGS), inclusive of exome sequencing (ES) and genome sequencing (GS). Currently, ES is offered widely in clinical settings, with a less prevalent...
7.
Wenzl K, Stokes M, Novak J, Bock A, Khan S, Hopper M, et al.
medRxiv
. 2023 Jun;
PMID: 37333387
Purpose: 60-70% of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients avoid events within 24 months of diagnosis (EFS24) and the remainder have poor outcomes. Recent genetic and molecular classification...
8.
Ansari-Pour N, Samur M, Flynt E, Gooding S, Towfic F, Stong N, et al.
Blood
. 2022 Oct;
141(6):620-633.
PMID: 36223594
Large-scale analyses of genomic data from patients with newly diagnosed multiple myeloma (ndMM) have been undertaken, however, large-scale analysis of relapsed/refractory MM (rrMM) has not been performed. We hypothesize that...
9.
Stong N, Ortiz-Estevez M, Towfic F, Samur M, Agarwal A, Corre J, et al.
Blood
. 2022 Aug;
141(13):1574-1583.
PMID: 35984902
Although translocation events between chromosome 4 (NSD2 gene) and chromosome 14 (immunoglobulin heavy chain [IgH] locus) (t(4;14)) is considered high risk in newly diagnosed multiple myeloma (NDMM), only ∼30% to...
10.
Barish S, Senturk M, Schoch K, Minogue A, Lopergolo D, Fallerini C, et al.
Hum Mol Genet
. 2022 Apr;
31(17):2934-2950.
PMID: 35405010
DROSHA encodes a ribonuclease that is a subunit of the Microprocessor complex and is involved in the first step of microRNA (miRNA) biogenesis. To date, DROSHA has not yet been...